Synthes and Lilly Sign Development and Collaboration Agreement
- Details
- Category: Eli Lilly and Company
Synthes, Inc. (SIX: SYST.VX) and Eli Lilly and Company (NYSE: LLY) announced the signing of an exclusive worldwide collaboration agreement to address the needs of patients who are cared for by orthopedic surgeons, including those with osteoporosis and those with bone fractures.
GlaxoSmithKline and Valeant announce US FDA approval of Potiga™ (ezogabine)
- Details
- Category: GlaxoSmithKline
GlaxoSmithKline (NYSE: GSK) and Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX) announced today that the U.S. Food and Drug Administration (FDA) has approved Potiga™ (ezogabine) Tablets, a potassium channel opener, as adjunctive treatment of partial-onset seizures in patients aged 18 years and older.
Abbott Reports Interim Results From Phase III Open-Label Study of Investigational Treatment for Advanced Parkinson's Disease
- Details
- Category: Abbott
Interim efficacy and safety results from a long-term, 54-week, Phase III open-label study of Abbott's investigational treatment for advanced Parkinson's disease showed that patients treated with levodopa-carbidopa intestinal gel (LCIG) for 12 weeks reported a decrease in "off" time and an increase in "on" time without troublesome dyskinesias.
Millions of children in the world's poorest countries could receive vaccination against rotavirus diarrhoeal disease
- Details
- Category: GlaxoSmithKline
GSK announced that it has made a new offer to supplyits rotavirus vaccine, RotarixTM, to the GAVI Alliance at $2.50 per dose, a small fraction of developed world prices.
Pfizer Conducts First "Virtual" Clinical Trial Allowing Patients to Participate Regardless of Geography
- Details
- Category: Pfizer
Pfizer Inc. is conducting the first-ever randomized clinical trial under an investigational new drug (IND) application that manages study participation entirely using electronic tools and allows patients to participate in the clinical trial regardless of their proximity to clinical sites.
Novartis drug Glivec® shows significant overall survival benefit
- Details
- Category: Novartis
Novartis announced new data showing a significant improvement in both recurrence-free survival and overall survival for patients taking Glivec® (imatinib) for three years after surgery to remove KIT (CD117)-positive gastrointestinal stromal tumors (GIST) compared to one year of treatment.
Pfizer and Hisun Sign MOU to Establish a Joint Venture
- Details
- Category: Pfizer
Pfizer Inc. (NYSE: PFE) and Zhejiang Hisun Pharmaceuticals (SSE stock code 600267), a leading pharmaceutical company in China, jointly announced the signing of a memorandum of understanding (MOU) on their intention to establish a joint venture.
More Pharma News ...
- Bristol-Myers Squibb and Roche Enter into a Clinical Collaboration Agreement
- Novartis highlights extensive data on numerous compounds at ASCO
- AstraZeneca and Heptares collaborate to investigate important GPCR drug targets
- Sanofi and DNDi - Drugs for Neglected Diseases initiative - Sign an Innovative Agreement
- RoACTEMRA could change the current standard of treatment for people living with rheumatoid arthritis
- Pfizer Announces New Strategic Partnerships with ICON and PAREXEL International Corporation
- Major Subgroup Analysis Shows Bayer's Rivaroxaban is Highly Effective in the Prevention of Recurrent Strokes